Anticoagulants & Analgesics Flashcards
venous thromboembolism (VTE) - hereditary risk factors
*factor V Leiden mutation
*Protein C or S deficiency
*hyperhomocysteinemia
*prothrombin gene mutation
*decreased factor VIII levels
*dysfibroginemia
*antithrombin deficiency
venous thromboembolism (VTE) - acquired risk factors
*surgery
*trauma
*medical illness
*immobolization
*pregnancy
*contraception/HRT
*indwelling catheters
*malignancy
*air travel
venous thromboembolism (VTE) in malignancy
*key risk factor: HYPERCOAGULABILITY
-mucin production by adenocarcinomas
-tissue factor production
*risk is higher in certain tumor types: pancreatic cancer, lung cancer, breast cancer, CNS malignancies
4 classes of anticoagulants
- heparins
- vitamin K antagonists
- direct thrombin inhibitors
- factor Xa inhibitors
anticoagulant class: heparins - MOA
*activates antithrombin, which decreases action primarily of factors IIa (thrombin) and Xa
*has its predominant impact on the intrinsic (PTT) pathway of the coagulation cascade
indications for heparin
*immediate anticoagulation for:
-VTE prophylaxis/treatment [pulmonary embolism, DVT]
-acute coronary syndrome
-MI
-percutaneous coronary intervention
heparins - ADEs
*heparin-induced thrombocytopenia (HIT)
*bleeding
note - monitor PTT of pts on heparin
what lab test should you monitor in patients on heparin
PTT
heparin-induced thrombocytopenia (HIT) - pathophysiology
*complication of therapy with heparins
*development of IgG antibodies against heparin-bound platelete factor 4:
-antibody-heparin-PF4 complex binds and activates platelets, leading to removal by splenic macrophages and therefore LOW PLATELET COUNTS
*tx - discontinue heparin and start an alternative anticoagulant
heparin-induced thrombocytopenia (HIT) - diagnosis
*serotonin release assay = diagnostic gold standard
*4T score: thrombocytopenia, timing of platelet fall coincides with heparin use, thrombosis, oTher causes (injury, fall, etc)
heparin-induced thrombocytopenia (HIT) - management
*stop all heparin products
*initiate therapy with alternative anticoagulant (bivalirudin, argatroban, fondaparinux)
*note - reexposure to heparin should be avoided
low molecular weight heparin - examples
*enoxaparin
*dalteparin
low molecular weight heparin - MOA
*activate antithrombin → act mainly on decreasing factor Xa
enoxaparin
*example of a low molecular weight heparin
*indications:
-VTE prophylaxis/treatment
-acute coronary syndrome
*ADEs: heparin-induced thrombocytopenia, bleeding
dalteparin
*example of low molecular weight heparin
*indications:
-VTE prophylaxis/treatment
-myocardial infarction
*ADEs: heparin-induced thrombocytopenia, bleeding
note - not as commonly used in the US
what is the reversal agent for heparin
PROTAMINE SULFATE
protamine sulfate
*reversal agent of heparin
*MOA: positively charged peptide that binds negatively charged heparin
*indications: unfractionated and low molecular weight heparin overdosage/associated hemorrhage
*ADEs:
-hypersensitivity
-pulmonary hypertension
-dyspnea
vitamin K antagonists (warfarin) - MOA
*inhibits vitamin K epoxide reductase
*inhibits vitamin K-dependent clotting factors: factors II, VII, IX, and X
*also inhibits proteins C and S (which are anticoagulants)
*has its predominant impact on the extrinsic pathway of the coagulation cascade
warfarin - MOA
vitamin K antagonist (inhibits vitamin K epoxide reductase → decreased production of factors II, VII, IX, and X and proteins C and S)
warfarin - indications
*VTE treatment
*chronic anticoagulation
warfarin - onset of action
*vitamin K inhibition: takes about 5 days
*HYPERcoagulability for 0-48 hours after 1st dose; therefore, you have to “bridge them”
what lab test should you monitor in patients on warfarin
PT/INR
INR monitoring for patients on warfarin
*goal of therapy = INR
*INR monitoring:
-weekly during initiation/major dose adjustment
-monthly during maintenance
warfarin drug-drug interactions
*CYP2C9 inhibitors/inducers (fluconazole, amiodarone, rifampin)
*chemotherapy agents (capecitabine, aprepitant)
*oral contraceptives
warfarin food interactions
*green, leafy veggies (kale, turnip greens, iceberg lettuce)
*cereal
*lamb
essentially, you would need to eat these regularly and in consistent amounts; if not, there will be INR fluctuations
warfarin ADEs
*teratogenic effects
*skin/tissue necrosis (due to hypercoagulable state)
*vasculitis
reversal of warfarin
*Vitamin K (slow reversal)
*Kcentra (rapid reversal):
-4 factor prothrombin complex
-ADEs: headache, N/V, arthralgia, hypotension, stroke, DVT,PE
examples of direct thrombin inhibitors
*bivalirudin
*argatroban
*dabigatraban
bivalirudin - MOA
*directly inhibits thrombin (factor IIa)
bivalirudin - indications & ADEs
*indications: percutaneous coronary intervention; treatment of HIT
*ADEs: back pain, bleeding
argatroban - MOA
*directly inhibits thrombin (factor IIa)
argatroban - indications & ADEs
*indications: percutaneous coronary intervention, treatment of HIT
*ADEs: hypotension, bleedingg
*note - with co-administration with warfarin, argatroban can cause artificially high INR but it is purely lab artifact
dabigatran - MOA
*directly inhibits thrombin (factor IIa)
dabigatran - indications & ADEs
*indications: primary or secondary VTE prevention
*ADEs: dyspepsia, bleeding, drug interactions
dabigatran - reversal
*idarucizumab
*monoclonal antibody that binds dabigatran and its metabolites
examples of factor Xa inhibitors
*apixaban
*edoxaban
*rivaroxaban
*fondaparinux
*betrixaban
note - naming convention: usually have an “x” in them or end with “-xaban”
fondaparinux - MOA
*directly inhibits factor Xa
rivaroxaban - MOA
*directly inhibits factor Xa
apixaban - MOA
*directly inhibits factor Xa
edoxaban - MOA
*directly inhibits factor Xa
betrixaban - MOA
*directly inhibits factor Xa
fondaparinux - indications & ADEs
*indications: VTE prophylaxis/treatment, acute coronary syndrome, treatment of HIT
*ADEs: fever, nausea, bleeding
rivaroxaban - indications & ADEs
*indications: VTE prevention/treatment
*ADEs: bleeding, increased liver enzymes
apixaban - indications & ADEs
*indications: prevention/treatment of VTEs
*ADEs: increased liver enzymes, bleeding
what is the reversal agent of factor Xa inhibitors
andexanet alfa
andexanet alfa
*factor Xa inhibitor reversal agent
*MOA: recombinant inactive form of factor Xa that acts as a decoy to bind anticoagulant
*ADEs: thromboembolic events, infusion site reaction
pain classification: nociceptive pain
*musculoskeletal conditions
*inflammation
*direct tissue injury
pain classification: neuropathic pain
*result of damage to nervous system
*acquired in most cases
pathogenesis of acute cancer pain
- most related to iatrogenic sources (diagnostic tests/procedures or treatment of disease)
- can be related to the disease itself:
-bone pain from pathologic fracture
-visceral pain from acute obstruction - adverse effects of treatment for cancer:
-mucositis from chemotherapy or radiation
-chemo induced neuropathy
pathogenesis of chronic cancer pain
- tumor-related somatic pain:
-bone pain from bone metastases
-visceral pain from organ/soft tissue metastases - tumor-related neuropathic pain:
-leptomeningeal metastases
-paraneoplastic syndromes (osteoarthropathy)
challenges in treatment of cancer pain
*route of administration (mechanical and physiologic challenges)
*drug-seeking vs. true pain
*acute variance in pain
*adverse effect management
WHO pain management algorithm ladder
*mild to moderate pain [scores 1-3]: treat with non-opioid analgesics (NSAIDs, acetaminophen)
*moderate to severe pain [scores 4-6 or 7]: mild opioids (e.g. codeine)
*severe pain [scores 7-10]: strong opioids (e.g. morphine)
classes of analgesic agents
- non-opioid analgesics (acetaminophen, NSAIDs)
- opioid analgesics
- anticonvulsants
- antidepressants
acetaminophen - MOA, drug class, indication
*MOA: prostaglandin blockade/inhibition
*drug class: non-opioid analgesics
*indication: mild to moderate pain [scores 1-3]
acetaminophen - ADEs
*hepatotoxicity!
*masks a fever (important in oncology population)
NSAIDs - examples
- salicylates (aspirin)
- propionic acids (ibuprofen, naproxen, ketoprofen)
- acetic acids (diclofenac, etodolac, sulindac, indomethacin, ketorolac)
- oxicams (meloxicam, piroxicam)
NSAIDs - MOA, drug class, indications
*MOA: COX inhibitors
*drug class: non-opioid analgesics
*indications: mild to moderate pain [scores 1-3]
NSAIDs - ADEs
*platelet inhibition
*gastrointestinal insult
*renal insult
COX-2 inhibitor
*celecoxib is the only agent approved
*MOA: selective for COX-2 inhibition
*ADEs: peripheral edema, myocardial infarction, nephrotoxicity
tramadol - MOA and drug class
*MOA: mu-receptor binding, serotonin/norepinephrine reuptake blockade
*drug class: mild opioid
*indication: moderate to severe pain [score 4-7/7]
tramadol - ADEs
*nausea
*constipation
*headache
opioid analgesics - MOA
*work on 3 different receptors: Mu, delta, and kappa (activates the Mu receptor predominantly)
*Mu receptors are concentrated in midbrain and dorsal horn
opioid analgesics - class ADEs
*sedation (tolerance develops)
*nausea/vomiting (tolerance develops)
*constipation (tolerance does NOT develop; prevention is key)
*euphoria/dysphoria - related to rate of administration
opioid-induced constipation
*result of Mu-receptor activation in the gut
*prophylaxis is a must (stimulant laxatives + stool softener)
extended-release opioids: REMS
*all extended-release opioids require enrollment by the prescribed and the pharmacy in the REMS program
*purpose = heighten awareness of risks of inappropriate use
*require medication guide dispensing at each fill of a prescription by pharmacy
mild opioids: indications & examples
*indication: first-line agents for patients with moderate to severe pain [score: 4-6/7]
*examples:
-codeine
-hydrocodone
morphine: drug class & indications
*drug class: strong opioid
*indication: severe pain [score: 7-10]
oxycodone: drug class & indications
*drug class: strong opioid
*indication: severe pain [score: 7-10]
hydromorphone: drug class & indications
*drug class: strong opioid
*indication: severe pain [score: 7-10]
oxymorphone: drug class & indications
*drug class: strong opioid
*indication: severe pain [score: 7-10]
fentanyl: drug class & indications
*drug class: strong opioid
*indication: severe pain [score: 7-10]
fentanyl dosage forms available
*IV/IM
*transmucosal
*transdermal
*buccal film
*sublingual liquid/spray
*buccal tablet
*oral lozenge
*intranasal solution
*sublingual tablet
methadone: MOA & drug class & indications
*MOA: Mu activation/NMDA-receptor inhibition
*drug class: strong opioid
*indication: severe pain [score: 7-10], OPIATE DETOXIFICATION
*available forms: oral tablet, oral solution, injection
buprenorphine: drug class, indication
*drug class: partial opioid agonist
*indication: chronic severe pain
*ADE: QTc prolongation
naloxone - MOA, indication
*used for opioid REVERSAL
*MOA: competes and displaces opioids at all Mu receptor sites
what drug is used for opioid reversal
naloxone
anticonvulsants - MOA, indications, ADEs
*MOA: bind to voltage-gated calcium channels and block GABA receptor
*used in treatment of NEUROPATHIC PAIN
*ADEs: dizziness, somnolence
gabapentin: drug class, indications, MOA
*drug class: anticonvulsant
*indications: used effectively in post-herpetic neuralgias, but also used in new onset neuropathies
*MOA: bind to voltage-gated calcium channels and block GABA receptor
note - SLOW onset of improvement
pregabalin: drug class, indications, MOA
*drug class: anticonvulsant
*indications: used effectively in post-herpetic neuralgias, but also used in new onset neuropathies
*MOA: bind to voltage-gated calcium channels and block GABA receptor
note - works faster than gabapentin
antidepressant pain MOA
*serotonin-norepinephrine reuptake inhibitors possess analgesic qualities
*full mechanism not understood, but effects on NEUROPATHIC pain are well established
venlafaxine: drug class, indication, ADEs
*drug class: antidepressant
*indications: neuropathic pain
*ADEs: cardiac conduction abnormalities, hypertension
*note - SLOW onset of improvement
duloxetine: drug class, indication, ADEs
*drug class: antidepressant
*indications: neuropathic pain - chronic low back pain, osteoarthritis, diabetic peripheral neuropathy
*ADEs: nausea, dry mouth, insomnia, constipation
*note - SLOW onset of improvement